ValiRx plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women’s health and The Royal Institute for the Advancement of Learning/McGill University (“McGill”), a Canadian based
ValiRx plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women’s health and The Royal Institute for the Advancement of Learning/McGill University (“McGill”), a Canadian based
Ambrose Healthcare Exercise Option on VAL 401 Out License Agreement for £16 Million plus Royalties
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, provides the following update at the conclusion of the Evaluation project from
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health announces that, further to the amendment to the Letter of Intent (“LOI”)
Update on proposed sub-license of VAL201
ValiRx plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women’s health, is today pleased to provide an operational update.
ValiRx Plc (AIM: VAL), a life science company focusing on cancer therapeutics and women’s health, announces that ValiSeek Limited (“ValiSeek”), has entered into an exclusive Option Agreement to license VAL401
ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today pleased to announce that the evaluation agreement announced on 14 February 2022
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce today the signature of a lease for
Launch of Broker Offer to raise a maximum of £500,000
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today provides an update on operational activities and strategy.
Live Q&A: London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, invites shareholders to join the CEO, Suzy Dilly and